Using its drug discovery platform, Verseon Corp, Fremont, Calif, has produced multiple novel anticoagulant candidates for the treatment of cardiovascular disorders, such as stroke prevention for nonvalvular atrial fibrillation patients, venous thromboembolism, and acute coronary syndrome. The company’s anticoagulant candidates are potent and selective direct thrombin inhibitors (DTIs) that bind to thrombin through a unique mechanism of action via reversible, covalent inhibition. This mechanism is responsible for the novel pharmacology of the DTIs and distinguishes them from existing oral anticoagulants. The candidates have demonstrated comparable preclinical efficacy to existing anticoagulants, but with substantially lower bleeding liability. They have pharmacokinetic profiles with half-lives, exposure, and bioavailability suitable for oral dosing. For more information, visit Verseon.
